		USD	INR (' In Thousands)	USD	INR (' In Thousands)
		As	at	As	
	Notes	31 Marc	ch 2018	31 Mar	ch 2017
ASSETS					
Non-current assets					
Financial assets					
Long-term loans and advances	1	3,823	249	3,579	232
Total non-current assets		3,823	249	3,579	232
Current assets					
Financial assets					
Cash and cash equivalents	2	945	62	945	61
Other current assets	3	1,901	124	1,790	116
Total current assets	0.5	2,846	185	2,735	177
Total assets		6,669	435	6,314	409
EQUITY AND LIABILITIES					
Equity					
Equity share capital	4	1,371,501	68,559	1,371,501	68,559
Other equity		(1,417,512)	(71,558)	(1,404,894)	(70,725)
Total equity		(46,011)	(2,999)	(33,393)	(2,166)
LIABILITIES					
Current liabilities					
Financial liabilities					
Trade payables	5	52,678	3,434	39,707	2,575
Total current liabilities		52,678	3,434	39,707	2,575
Total liabilities		52,678	3,434	39,707	2,575
Total equity and liabilities		6,669	435	6,314	409

Rajneesh Gupta

Vice President - Finance

Place: Noida Date: 9 May, 2018

Jubilant Biosys Singapore Pte. Limited Statement of Profit and Loss for the year ended 31 March 2018

		USD	INR (' In Thousands)	USD	INR (' In Thousands)
Particulars	Notes		year ended arch 2018	For the ye	
Expenses	(12 (10	012	1 210 (20	00 455
Other expenses Total expenses	6	12,618 12,618	812 812	1,318,639 1,318,639	88,455 88,455
Loss before tax		(12,618)	(812)	(1,318,639)	(88,455)
Tax expense					
- Current tax					
Total tax expense		-	-	2.	74
Loss after tax		(12,618)	(812)	(1,318,639)	(88,455)
Other comprehensive income					
Items that will not be reclassified to profit or loss					
Exchange differences on translation of foreign operations			(21)		(1,772)
Other comprehensive income for the year, net of tax			(21)	ž.	(1,772)
Total comprehensive income for the year		(12,618)	(833)	(1,318,639)	(90,227)

Rajneesh Gupta

Vice President - Finance

Place: Noida

Date: 9 May, 2018

		Reserves and surplus							
	Retained	Exchange differnces on translation of foreign	To	tal					
	**-	INR (' In	INR (' In		INR (' In				
	USD	Thousands)	Thousands)	USD	Thousands)				
Balance as at 1 April 2016	(86,255)	11,742	7,760	(86,255)	16,588				
Loss for the year	(1,318,639)	(88,455)	1.21	(1,318,639)	(88,455)				
Exchange differences on translation of									
foreign operations		3	(1,772)	2.5	(1,772)				
Balance as at 31 March 2017	(1,404,894)	(76,713)	5,988	(1,404,894)	(70,725)				
Loss for the year	(12,618)	(812)		(12,618)	(812)				
Exchange differences on translation of	(-,,	(-,		, , , ,	()				
foreign operations			(21)		(21)				
Balance as at 31 March 2018	(1,417,512)	(77,525)	5,967	(1,417,512)	(71,558)				

Rajneesh Gupta Vice President - Finance Place: Noida Date: 9 May, 2018

Jubilant Biosys Singapore Pte Limited Statement of Cash Flows for the year ended 31 March 2018

	areunus /	INR (' In		INR (' In
	USD	Thousands)	USD	Thousands)
Particulars		year ended rch 2018	For the ye	
	O 1 1110	10110	OI HIMI	2017
A. Cash flow from operating activities				
Loss before tax	(12,618)	(812)	(1,318,639)	(88,455)
Adjustments:				
Provision for diminution in value of investment	E	P	1,306,552	87,644
Operating cash flow before working capital changes				
Increase/(decrease) in other current assets and loan and advances	(354)	(23)	119	7
Increase in trade payables	12,972	837	11,938	801
Cash generated from operations	15.	2	(30)	(3)
Income tax paid (net of refund)	7 <u>2</u> 2	#9	2 4 :	<u></u>
Net cash from/(used in) used in operating activities		2	(30)	(3)
B. Effect of exchange rate changes		(2)		(1)
Net decrease in cash and cash equivalents (A+B)	:*:	(0)	(30)	(4)
Add: cash and cash equivalents at the beginning of year	945	61	975	65
Cash and cash equivalents at the end of the year	945	62	945	61

Rajneesh Gupta

Vice President - Finance

Place: Noida

Date: 9 May, 2018

Jubilant Biosys Singapore Pte. Limited Notes to the financial statements for the year ended 31 March 2018

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	As at 31 I	March 2018	As at 31 M	farch 2017
Note 1. Long term loan and advances				
Security deposits	3,823	249	3,579	232
	3,823	249	3,579	232
Note 2. Cash and cash equivalent				
Balances with banks:				
- On current accounts	945	62	945	61
	945	62	945	61
Note 3. Other current assets				
Prepaid expenses	1,901	124	1,790	116
	1,901	124	1,790	116

Note 4: Equity share capital

	USD I	VR (' In	USD I	NR (' li
	T	housands)	Т	housands)
	As at 31 Mai	rch 2018	As at 31 N	March 2017
Issued, subscribed and paid up share capital				
1,371,501 (31 March 2017: 1,371,501 equity shares with no par value	1,371,501	68,559	1,371,501	68,559
	1,371,501	68,559	1,371,501	68,559

1) Movement in equity share capital

			INR (' In
Note	No. of shares	USD	Thousands)
4	1,371,501	1,371,501	68,559
			(#)
4	1,371,501	1,371,501	68,559
			220
4	1,371,501	1,371,501	68,559
	4	4 1,371,501 4 1,371,501	4 1,371,501 1,371,501 4 1,371,501 1,371,501

²⁾ The Company has only one class of shares referred to as equity shares having no par value. Each holder of equity shares is entitled to one vote per share.

4) The details of shareholders holding more than 5% shares in the company: -

	A	s at	As at		
	31 March 2018		31 Marc	h 2017	
	No. of shares	% holding in the class	No. of shares	% holding in the class	
Name of the Shareholder					
Jubilant Biosys (BVI) Limited	1,371,501	100%	1,371,501	100%	

³⁾ In the event of liquidation of the Company, the holders of equity shares will be entitled to receive any of the remaining assets of the Company after distribution of all preferential amounts, if any, in proportion to their shareholding. However no such preferential amounts exist currently.

Jubilant Biosys Singapore Pte. Limited Notes to the financial statements for the year ended 31 March 2018

	USD	INR (' In	USD	INR (' In
		Thousands)		Thousands)
	As at 31 M	March 2018	As at 31 M	larch 2017
Note 5. Trade payables				
Trade payables-others	52,678	3,434	39,707	2,575
	52,678	3,434	39,707	2,575

Jubilant Biosys Singapore Pte. Limited Notes to the financial statements for the year ended 31 March 2018

	USD	INR (' In Thousands)	USD	INR (' In Thousands)
	For the yea 31 Marci		For the year	
Note 6. Other expenses				
Auditors remuneration	4,159	268	3,756	252
Legal, professional and consultancy charges	8,703	560	8,159	547
Bank charges	74.5	5 - 5	30	2
Loss on impairement	120	-	1,306,552	87,644
Foreign exchange loss/(gain)	(244)	(16)	142	10
	12,618	812	1,318,639	88,455